Baricitinib for treating moderate to severe atopic dermatitis was due to pause , however the topic will now continue on the original timelines and will no longer pause.
The timelines are subject to staff capacity and the ongoing management of the COVID-19 situation and we will continue to review our plans and update our stakeholders accordingly.